



Shield TX (UK) Ltd

Methodological note

Shield Therapeutics is a specialty pharmaceutical company focused on the development and commercialisation of late-stage, hospital-focused pharmaceuticals which address areas of unmet medical need. Shield commercially launched its first product, Feraccru, in 2016 in the UK and Germany. Part of the launch campaign strategy has been to raise awareness of the benefits Feraccru can provide to patients with inflammatory bowel disease (IBD) associated with Iron Deficiency Anaemia (IDA). In September 2018 Shield entered into a licensing agreement with Norgine B.V. under which commercialisation arrangements for Feraccru in Europe transferred to Norgine from early 2019.

Shield is committed to upholding the highest standards of ethics in the pharmaceutical industry and hereby presents the company methodological note pursuant to Clause 24 of the ABPI Code of Practice relating disclosure of Transfers of Value payments made to HCPs and HCOs during 2016.

Definitions

Healthcare Professionals (HCPs)

Extract from ABPI code “1.4 The term ‘health professional’ includes members of the medical, dental, pharmacy and nursing professions and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine. 1.5 The term ‘other relevant decision makers’ particularly includes those with an NHS role who could influence in any way the administration, consumption, prescription, purchase, recommendation, sale, supply or use of any medicine but who are not health professionals.”

Healthcare Organisations (HCOs)

Extract from ABPI Code “1.9 The term ‘healthcare organisation’ means either a healthcare, medical or scientific association or organisation such as a hospital, clinic, foundation, university or other teaching institution or learned society whose business address, place of incorporation or primary place of operation is in Europe or an organisation through which one or more health professionals or other relevant decision makers provide services.”

Disclosure

In 2018 Shield disclosed the following financial payments:

1. Transfers of value to named individual healthcare professionals (HCPs) who have given their consent to disclose for fees received in the provision of providing consultancy services and expenses relating to those consultancy services.
2. Transfers of value to healthcare organisations (HCOs) in relation to sponsorship fees in association with specific meetings or exhibitions



Shield TX (UK) Ltd

Methodological note

TOV Transaction Principles

Transaction date

Payments have been disclosed using the invoice date as a reference point to the relevant calendar year. Invoices have been received and processed on a timely basis and all payments relating to activities carried out in 2018 have been disclosed.

Taxes

VAT has been excluded from the ToV disclosure amounts. Income tax and National Insurance are not applicable to the payments made.

Multi-year projects

Payments are accounted for on an invoice basis and therefore where applicable will be disclosed in the year the invoice is received. At the end of 2018 there were no projects for which an invoice was outstanding.

Cross border payments

During 2018 a small number of payments were made to overseas physicians. The payments were made from the UK affiliate company, Shield TX (UK) Limited and have therefore been disclosed in the UK.

HCP Payments

Data privacy

Shield has obtained consent from HCPs for disclosure to the ABPI for payments subject to ToV. Where consent has not been obtained, this information has been provided under the aggregate totals provided.

HCO Payments

Payments provided to HCO organisations have been disclosed and include payments for sponsorship and meeting space.

Over-the-counter ToV

No payments and therefore no disclosures were made during the year with regards to over-the-counter ToV payments.

Medical Devices

No medical device ToV payments were made during the period.